{"contentid": 488013, "importid": NaN, "name": "STADA Arz achieves 15% profit growth to 713 million euros", "introduction": "STADA Arzneimittel, the Germany-based drugmaker owned by UK private equity funds Cinven and Bain Capital, has reported revenues of 3 billion euros ($3.6 billion) for full-year 2020, alongside double-digit growth well ahead of the market.", "content": "<p>STADA Arzneimittel, the Germany-based drugmaker owned by UK private equity funds Cinven and Bain Capital, has reported revenues of 3 billion euros ($3.6 billion) for full-year 2020, alongside double-digit growth well ahead of the market.</p>\n<p>Organic sales growth of 6% and total growth of 18% in a flat market were complemented by seven acquisitions and more than 80 in-licensing transactions closed during 2020, the company noted.</p>\n<p>Earnings before interest, tax, depreciation and amortization (EBITDA) increasing by 15% at constant currencies to 713 million euros. Investments in the supply chain strengthened STADA&rsquo;s sustainability, with record output, strong supply levels and zero critical observations from regulatory inspections of manufacturing facilities in 2020.</p>\n<p>&ldquo;Our above-market sales and profit increases reflect the extraordinary engagement and entrepreneurship of our diverse global workforce,&rdquo; STADA&rsquo;s chief executive Peter Goldschmidt stated. &ldquo;Our strategy to position STADA as the go-to-partner for consumer healthcare, specialty pharmaceuticals and generics is succeeding.&rdquo; STADA closed seven deals in total, including the acquisition of Walmark vitamins, minerals and food supplements in Central and Eastern Europe, a portfolio from GSK and former Takeda brands in Russia and CIS. Additionally, more than 80 in-licensing deals were closed during 2020,&rdquo; he noted.</p>\n<p>During 2020, STADA became number four in the European generics market and increased its ranking from number nine to number five in the European consumer healthcare market. Outside of Europe, STADA continued to strengthen its presence in selected Asian markets such as China, the Philippines and Vietnam, as well as in the Middle East and North Africa.</p>\n<p>Consumer Healthcare and Specialty brands now account for around half of STADA&rsquo;s group sales in 2020. These products have the potential to offer sustainable and growing margins over many years.</p>\n<h2><strong>STADA&rsquo;s optimistic outlook in 2021</strong></h2>\n<p>Through a clear growth strategy that is based on a shared purpose, vision and set of values, the business expects a continuation of its growth journey in 2021. Outlining reasons for this optimistic outlook for 2021, Mr Goldschmidt observed that STADA enjoys a well-stocked Generics pipeline, while the group&rsquo;s Specialty presence is expanding through biosimilar partnerships and through launches such as the entry of a novel patented product for late-stage Parkinson&rsquo;s disease.</p>\n<p>With STADA continuing to evaluate further acquisitions, in-licensing and business-development opportunities, the group is confident of delivering further organic and inorganic growth in 2021.</p>\n<p>&ldquo;As a go-to-partner for consumer healthcare, specialty pharmaceuticals and generics, STADA is broadening its portfolio and delivering on our purpose of caring for people&rsquo;s health as a trusted partner,&rdquo; Mr Goldschmidt concluded.</p>", "date": "2021-03-11 15:03:00", "meta_title": "STADA Arz achieves 15% profit growth to 713 million euros", "meta_keywords": "STADA Arzneimittel, Financial results, Full-year, 2020", "meta_description": "STADA Arz achieves 15% profit growth to 713 million euros", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-11 15:01:47", "updated": "2021-03-11 15:09:07", "access": NaN, "url": "https://www.thepharmaletter.com/article/stada-arz-achieves-15-profit-growth-to-713-million-euros", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "stada-location-big.jpg", "image2id": "stada-location-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Generics", "therapy area_tag": NaN, "topic_tag": "Financial, Management", "geography_tag": "Germany", "company_tag": "BAIN CAPITAL&#44;&nbsp; LP, STADA Arzneimittel", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-11 15:03:00"}